The NCIC CTG and AGITG CO.23 trial: A phase III randomized study of BBI608 plus best supportive care (BSC) versus placebo (PBO) plus BSC in patients (Pts) with pretreated advanced colorectal carcinoma (CRC).

被引：9
|
作者：
Jonker, Derek J.
Nott, Louise M.
Yoshino, Takayuki
Li, Chiang
Gill, Shariene
Shapiro, Jeremy David
Ohtsu, Atsushl
Zalcberg, John Raymond
Vickers, Michael M.
Slims, John
Wei, Alice Chia-Chi
Mittmann, Nicole
Magoski, Nadine M.
Murray, Yvonne
Tsobanis, Eric
Tu, Dongsheng
Kerstein, David
O'Callaghan, Christopher J.
机构：
[1] Ottawa Hosp Res Inst, Ottawa, ON, Canada
[2] Royal Hobart Hosp, Hobart, Tas, Australia
[3] Natl Canc Ctr Hosp East, Chiba, Japan
[4] Boston Biomed Inc, Cambridge, MA USA
[5] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[6] Cabrini Hosp, Melbourne, Vic, Australia
[7] Natl Canc Ctr, Exploratory Oncol Res & Clin Trial Ctr, Kashiwa, Chiba, Japan
[8] Peter MacCallum Canc Ctr, Melbourne, Vic, Australia
[9] Tom Baker Canc Clin, Calgary, AB, Canada
[10] NHMRC Clin Trials Ctr, Sydney, NSW, Australia
[11] Toronto Gen Hosp, Toronto, ON, Canada
[12] Sunnybrook Hlth Sci Ctr, HOPE Res Ctr, Toronto, ON M4N 3M5, Canada
[13] NCIC Clin Trials Grp, Kingston, ON, Canada
[14] NHMRC Clin Trials Ctr, Camperdown, NSW, Australia
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.tps3660
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
TPS3660
引用
收藏
页数：1
相关论文
共 50 条
  • [1] A randomized phase III study of napabucasin [BBI608] (NAPA) vs placebo (PBO) in patients (pts) with pretreated advanced colorectal cancer (ACRC): the CCTG/AGITG CO.23 trial
    Jonker, D. J.
    Nott, L.
    Yoshino, T.
    Gill, S.
    Shapiro, J.
    Ohtsu, A.
    Zalcberg, J.
    Vickers, M. M.
    Wei, A.
    Gao, Y.
    Tebbutt, N.
    Markman, B.
    Esaki, T.
    Koski, S.
    Hitron, M.
    Magoski, N. M.
    Simes, J.
    Li, C.
    Tu, D.
    O'Callaghan, C. J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [2] The influence of hypomagnesemia (hMg) on overall survival (OS) in a phase III randomized study of cetuximab (CET) plus best supportive care (BSC) versus BSC: NCIC CTG/AGITG CO.17
    Vickers, M. M.
    Karapetis, C. S.
    Tu, D.
    O'Callaghan, C. J.
    Price, T. J.
    Tebbutt, N. C.
    Van Hazel, G.
    Shapiro, J. D.
    Pavlakis, N.
    Gibbs, P.
    Blondal, J.
    Lee, U. J. Yu Min
    Meharchand, J. M.
    Burkes, R. L.
    Rubin, S. H.
    Simes, J.
    Zalcberg, J. R.
    Moore, M. J.
    Zhu, L.
    Jonker, D. J.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [3] Maintenance pemetrexed plus best supportive care (BSC) versus placebo plus BSC: A phase III study
    Ciuleanu, T. E.
    Brodowicz, T.
    Belani, C. P.
    Kim, J.
    Krzakowski, M.
    Laack, E.
    Wu, Y.
    Peterson, P.
    Adachi, S.
    Zielinski, C. C.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [4] Nintedanib plus best supportive care (BSC) versus placebo plus BSC for the treatment of patients (pts) with colorectal cancer (CRC) refractory to standard therapies: Results of the phase III LUME-colon 1 study
    Van Cutsem, E.
    Yoshino, T.
    Lenz, H-J.
    Lonardi, S.
    Falcone, A.
    Limon, M. L.
    Saunders, M. P.
    Sobrero, A.
    Maiello, E.
    Park, Y. S.
    Ferreiro Monteagudo, R.
    Hong, Y. S.
    Tomasek, J.
    Taniguchi, H.
    Ciardiello, F.
    Hocke, J.
    Oum'hamed, Z.
    Vlassak, S.
    Studeny, M.
    Tabernero, J.
    ANNALS OF ONCOLOGY, 2016, 27
  • [5] A randomized phase III trial comparing sorafenib plus best supportive care (BSC) versus BSC alone in Child-Pugh B patients (pts) with advanced hepatocellular carcinoma (HCC): The BOOST study
    Daniele, Bruno
    Di Maio, Massimo
    Gallo, Ciro
    Gasbarrini, Antonio
    Carteni, Giacomo
    Di Costanzo, Giovan Giuseppe
    Craxi, Antonio
    Cabibbo, Giuseppe
    Bolondi, Luigi
    Granito, Alessandro
    Missale, Gabriele
    Frassoldati, Antonio
    Angelico, Mario
    Roselli, Mario
    Daniele, Gennaro
    Perrone, Francesco
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [6] CCTG CO.26 trial: A phase II randomized study of durvalumab (D) plus tremelimumab (T) and best supportive care (BSC) versus BSC alone in patients (pts) with advanced refractory colorectal carcinoma (rCRC).
    Chen, Eric Xueyu
    Jonker, Derek J.
    Kennecke, Hagen F.
    Berry, Scott R.
    Couture, Felix
    Ahmad, Chaudhary E.
    Goffin, John R.
    Kavan, Petr
    Harb, Mohammed
    Colwell, Bruce
    Samimi, Setareh
    Samson, Benoit
    Abbas, Tahir
    Aucoin, Nathalie
    Aubin, Francine
    Koski, Sheryl L.
    Wei, Alice Chia-chi
    Magoski, Nadine M.
    Tu, Dongsheng
    O'Callaghan, Christopher J.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (04)
  • [7] LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
    Lenz, Heinz-Josef
    Tabernero, Josep
    Yoshino, Takayuki
    Oum'Hamed, Zohra
    Vlassak, Soetkin
    Sassi, Mouna
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [8] LUME-Colon 1: A double-blind, randomized phase III study of nintedanib plus best supportive care (BSC) versus placebo plus BSC in patients with colorectal cancer (CRC) refractory to standard therapies.
    Lenz, Heinz-Josef
    Tabernero, Josep
    Yoshino, Takayuki
    Oum'Hamed, Zohra
    Vlassak, Soetkin
    Sassi, Mouna
    Van Cutsem, Eric
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [9] Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17
    Vickers, M. M.
    Karapetis, C. S.
    Tu, D.
    O'Callaghan, C. J.
    Price, T. J.
    Tebbutt, N. C.
    Van Hazel, G.
    Shapiro, J. D.
    Pavlakis, N.
    Gibbs, P.
    Blondal, J.
    Lee, U.
    Meharchand, J. M.
    Burkes, R. L.
    Rubin, S. H.
    Simes, J.
    Zalcberg, J. R.
    Moore, M. J.
    Zhu, L.
    Jonker, D. J.
    ANNALS OF ONCOLOGY, 2013, 24 (04) : 953 - 960
  • [10] A randomized phase III trial comparing pemetrexed plus best supportive care (BSC) vs BSC in previously treated patients (PTS) with advanced malignant pleural mesothelioma (MPM)
    Jassem, Jacek
    Ramlau, Rodryg
    Santoro, Armando
    Schuette, Wolfgang
    Chemaissani, Assad
    Hong, Shengyan
    Blatter, Johannes
    Adachi, Susumu
    Hanauske, Axel-R
    Manegold, Christian
    ANNALS OF ONCOLOGY, 2006, 17 : 214 - 214
12345